The news is really good.
Apparently, Howard Marks, who is a large holder has written to the Board and asked for. Shake-up. About time |
So so undervalued. |
T/O Rumours? |
Odd little spike this afternoon, have taken that and sold the last of my shares at 753p. Best of luck for anyone still holding. |
P/E of just 5, prolific cash cow, strong growth prospects..too cheap |
 Ian Lyall
PROACTIVENEWS
Indivior shares motor 11% after reassuring update; brokers positive
Published: 11:50 24 Oct 2024 BST
Indivior PLC (LSE:INDV)’s share price jumped 11% after the company reaffirmed its full-year outlook despite recent challenges, including increased competition for its opioid addiction treatment, Sublocade.
In its third-quarter results, Indivior posted a 13% revenue increase to $307 million, with Sublocade sales rising 14% to $191 million.
The company addressed concerns over competitor Brixadi, stating it remains confident in Sublocade's leadership, which holds a mid-60% market share in key prescribing groups.
CEO Mark Crossley highlighted Sublocade’s differentiation, particularly in combating synthetic opioids, and reaffirmed the goal of achieving over $1.5 billion in peak revenue. Indivior is also streamlining its operations, aiming to cut operating expenses by up to $20 million in 2025.
"Headline [third quarter figures beat consensus due to strong Suboxone Film but Sublocade growth is flat QoQ [quarter-on-quarter]," said Jefferies in a note.
In late morning trade, the stock was up 74.5p at 725p. Jefferies says 'buy' up to 1,800p.
Fellow American bank Stifel restated its 'buy' and 1,400p price target, adding: "We are encouraged by the still more than 60% share for Sublocade by co-prescribers of both Sublocade and Brixadi, while the early and within-expectations settlement of the remaining antitrust cases is incrementally positive.
"After two profit warnings this year, we recognise the need to rebuild market confidence, but continue to believe market concerns implied by current low multiples...are overdone." |
4*
Indivior posted upbeat Q3 results and also announced that it had reached an expected settlement with certain end payors to resolve remaining antitrust cases. Total Q3 2024 net revenue (NR) of $307m was up +13% vs. Q3 2023 with ytd revenue up 11% to $889m. Of this SUBLOCADE® Q3 2024 NR of $191m was +14% vs. Q3 2023 taking YTD 2024 SUBLOCADE NR up to $562m which was +24% vs. YTD 2023. The impressive top line performance fed down to improved bottom line performance, Q3 2024 reported net income was $4m up from a Q3 2023...
...from WealthOracle
wealthoracle.co.uk/detailed-result-full/INDV/907 |
before today's rise we were 67% or so down from high. |
looking forward to the call at 1pm.just way too cheap |
Results seem to have been well received... |
This is just too cheap now |
thanks bulltradept |
No results on the company website, despite an RNS telling us they are there |
Slough, UK, and Richmond, VA, October 15, 2024 - Indivior PLC (NASDAQ/LSE: INDV) today announced that it will release its year-to-date and Q3 2024 results on October 24th at 7:00 a.m. London time (2:00 a.m. U.S. Eastern). The results will be available via the London Stock Exchange's Regulatory News Service (RNS) and on the "Investors" section of the company's website at www.indivior.com.Mark Crossley, Chief Executive Officer, and other members of Indivior's leadership team will host a presentation via live webcast at 1:00 p.m. London time (8:00 a.m. U.S. Eastern) on October 24th. |
Excellent article Waldron.
"An analysis of more than 500,000 people with a history of opioid-use disorder showed that more than 8,000 participants who were separately prescribed so-called GLP-1 drugs, such as Ozempic, had a 40 per cent lower rate of opioid overdose than those who did not.2 |
I still think a lot of the weakness in this and many other UK small caps is due to budget related issues (Capital gains tax, pension rule changes etc.) |
...and they are looking to cut costs and possibly cut prices to match the competition |
They no longer have the monopoly, the competition has eroded market share and will continually seek to further erode any market share and the company is swamped in litigation. The buyback I think will end in February, having commenced in August. |
just shows how pointless the move to the US stock market was |
still double the current price |
too cheap by any measure.. |
Register to chat with like-minded investors on our interactive forums.
Hot Features
Premium
